LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

Search

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

24.09 -0.33

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

23.58

Max

24.98

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-2.8M

-57M

Pardavimai

35K

730K

Pelnas, tenkantis vienai akcijai

-1.01

Pelno marža

-7,753.425

Darbuotojai

186

EBITDA

-1.1M

-63M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+115.63% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

58M

1.5B

Ankstesnė atidarymo kaina

24.42

Ankstesnė uždarymo kaina

24.09

Naujienos nuotaikos

By Acuity

50%

50%

182 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-12 21:55; UTC

Uždarbis

Xero Beats 1st Half Profit Expectations Despite Melio Margin Hit

2025-11-12 21:34; UTC

Uždarbis

Cisco Systems Boosts Fiscal Year Outlook as 1Q Profit, Revenue Rise

2025-11-12 23:44; UTC

Rinkos pokalbiai

Nikkei May Trade in Range Amid Caution Over U.S. Econ -- Market Talk

2025-11-12 23:38; UTC

Rinkos pokalbiai

Gold Steady Ahead of Expected End to U.S. Government Shutdown -- Market Talk

2025-11-12 23:13; UTC

Uždarbis

Samsung Fire & Marine Insurance 3Q Net Profit Largely Met FactSet-Compiled Consensus

2025-11-12 23:13; UTC

Uždarbis

Samsung Fire & Marine Insurance 3Q Net KRW538.50B Vs. Net KRW554.56B >000810.SE

2025-11-12 23:13; UTC

Uždarbis

Samsung Fire & Marine Insurance 3Q Oper Pft KRW664.06B Vs. Pft KRW717.46B >000810.SE

2025-11-12 23:13; UTC

Uždarbis

Samsung Fire & Marine Insurance 3Q Rev KRW5.732T Vs. KRW5.326T >000810.SE

2025-11-12 22:30; UTC

Rinkos pokalbiai
Uždarbis

Firefly Aerospace Sets Plan for Next Launch After Explosion -- Market Talk

2025-11-12 22:18; UTC

Uždarbis

Cisco Systems Boosts Outlook on AI-Driven Demand -- Update

2025-11-12 22:12; UTC

Rinkos pokalbiai

Bank of Canada Rate Hikes Could Start in 2H 2026 -- Market Talk

2025-11-12 22:05; UTC

Uždarbis

Pan American Silver: Campbell Succeeded Steve Busby >PAAS

2025-11-12 22:04; UTC

Uždarbis

Pan American Silver Named Scott Campbell as Operating Chief on Oct. 20

2025-11-12 22:04; UTC

Uždarbis

Pan American Silver 3Q Adj EPS 48c >PAAS

2025-11-12 22:04; UTC

Uždarbis

Pan American Silver 3Q Rev $884.4M >PAAS

2025-11-12 22:04; UTC

Uždarbis

Pan American Silver 3Q EPS 45c >PAAS

2025-11-12 22:03; UTC

Uždarbis

Manulife Financial: 3Q Book Value Per Common Shr C$26.07 >MFC.T

2025-11-12 22:02; UTC

Uždarbis

Manulife Financial 3Q Net C$1.8B >MFC

2025-11-12 22:02; UTC

Uždarbis

Manulife Financial 3Q Adj EPS C$1.16 >MFC

2025-11-12 22:02; UTC

Uždarbis

Manulife Financial 3Q EPS C$1.02 >MFC

2025-11-12 21:53; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel: Sale Strengthens Focus on Own Growth Investments

2025-11-12 21:53; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel Says Deal Subject to Indian Regulatory Approvals

2025-11-12 21:53; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel Estimates Net Profit After Tax on Sale of A$70 Million

2025-11-12 21:53; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel Expects Net Proceeds After Taxes, Fees of A$179 Million in 2H FY26

2025-11-12 21:52; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel: Tata BlueScope Steel JV a Provider of Coated, Painted Steel Products in India

2025-11-12 21:51; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel Agrees to Sell 50% Stake in Tata BlueScope Steel Joint Venture to Tata Steel

2025-11-12 21:50; UTC

Rinkos pokalbiai
Uždarbis

Basic Materials Roundup: Market Talk

2025-11-12 21:49; UTC

Uždarbis

Cisco Stock Climbs as Earnings Beat Expectations Amid Strong AI Demand -- Barrons.com

2025-11-12 21:48; UTC

Uždarbis

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares. -- Barrons.com

2025-11-12 21:40; UTC

Uždarbis

Xero Beats 1H Profit Expectations Despite Melio Margin Hit

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

115.63% į viršų

12 mėnesių prognozė

Vidutinis 52.55 USD  115.63%

Aukščiausias 90 USD

Žemiausias 21 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

13 ratings

12

Pirkti

0

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

182 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat